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Abstract
Background—Adams-Oliver syndrome (AOS) is a rare disorder characterized by congenital 
limb defects and scalp cutis aplasia. In a proportion of cases, notable cardiac involvement is also 
apparent. Despite recent advances in the understanding of the genetic basis of AOS, for the 
majority of affected subjects the underlying molecular defect remains unresolved. This study 
aimed to identify novel genetic determinants of AOS.
Methods and Results—Whole-exome sequencing was performed for 12 probands, each with a 
clinical diagnosis of AOS. Analyses led to the identification of novel heterozygous truncating 
NOTCH1 mutations (c.1649dupA and c.6049_6050delTC) in two kindreds in which AOS was 
segregating as an autosomal dominant trait. Screening a cohort of 52 unrelated AOS subjects, we 
detected 8 additional unique NOTCH1 mutations, including three de novo amino-acid 
substitutions, all within the ligand-binding domain. Congenital heart anomalies were noted in 47% 
(8/17) of NOTCH1-positive probands and affected family members. In leucocyte-derived RNA 
from subjects harboring NOTCH1 extracellular domain mutations, we observed significant 
reduction of NOTCH1 expression, suggesting instability and degradation of mutant mRNA 
transcripts by the cellular machinery. Transient transfection of mutagenized NOTCH1 missense 
constructs also revealed significant reduction in gene expression. Mutant NOTCH1 expression was 
associated with down-regulation of the Notch target genes HEY1 and HES1, indicating that 
NOTCH1-related AOS arises through dysregulation of the Notch signaling pathway.
Conclusions—These findings highlight a key role for NOTCH1 across a range of 
developmental anomalies that include cardiac defects, and implicate NOTCH1 haploinsufficiency 
as a likely molecular mechanism for this group of disorders.
Keywords
heart defects; congenital; genetics; human; Adams-Oliver syndrome; haploinsufficiency; 
NOTCH1
Introduction
Adams-Oliver syndrome (AOS; MIM 100300) is a rare developmental disorder, 
characterized by a range of abnormalities that include cranial aplasia cutis congenita (ACC) 
and terminal transverse limb defects (TTLD).1,2 The spectrum of defects observed implies 
dysregulation of multiple developmental pathways. Congenital heart defects (CHDs) have 
been reported in conjunction with AOS in up to 20% of cases and, when present, represent a 
serious mortality risk.3,4 Cardiac defects are also commonly associated with systemic 
structural vascular abnormalities, of which cutis marmorata telangiectatica congenita 
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(CMTC) is the most frequently described.5 AOS primarily segregates as an autosomal 
dominant trait with variable phenotypic expression. A small number of kindreds are 
consistent with autosomal recessive disease gene transmission. In addition, sporadic cases 
with comparable clinical features indicate the occurrence of de novo mutations in causative 
disease genes.
The molecular genetic basis of AOS appears heterogeneous and, to date, defects within five 
genes have been reported, providing limited insight as to the molecular mechanisms 
underlying these important aspects of early development. Mutations of the ARHGAP31 and 
DOCK6 genes underlie a proportion of AOS cases displaying autosomal dominant and 
recessive inheritance, respectively.6,7 Both ARHGAP31 and DOCK6 regulate the activity of 
the Rho GTPases Cdc42 and Rac1, which cycle between active, GTP-bound and inactive, 
GDP-bound states through the opposing modes of action of guanine nucleotide exchange 
factors (GEFs) and GTPase-activating proteins (GAPs). We have previously demonstrated 
that ARHGAP31 mutations cause AOS through a gain-of-function mechanism, which leads 
to an accumulation of inactive GTPase, disrupting actin cytoskeletal dynamics.6 Mutations 
in DOCK6 result in a more severe, multi-systemic phenotype due to a homozygous loss of 
GEF function.7
More recently, the Notch signaling pathway has been implicated in AOS pathogenesis by 
the discovery of heterozygous alterations in the RBPJ gene, encoding the major transcription 
factor for Notch.8 Missense mutations within the DNA-binding domain of RBPJ result in 
impaired binding ability of the transcription factor to the HES1 promoter, likely disrupting 
the regulation of Notch target genes downstream.8 Moreover, two independent studies have 
identified homozygous mutations of EOGT, encoding an EGF domain-specific enzyme 
demonstrated as critical in the glycosylation of Notch1 in mammalian cells.9,10 Most 
recently, a report by Stittrich et al. identified mutations of the NOTCH1 gene in a proportion 
of an AOS cohort.11
These studies have provided some important insights into the molecular processes key to the 
development of AOS. However, despite congenital heart anomalies affecting approximately 
1 in 5 subjects with AOS, the ARHGAP31- and RBPJ-positive pedigrees reported in the 
literature have a notable lack of cardiovascular involvement.6,8,12 Although the majority of 
these mutation carriers may not have been assessed by cardiac imaging, these data implicate 
distinct regulatory systems in the pathogenesis of autosomal dominant AOS with congenital 
heart defects. We designed an exome-wide based study, to further define the genetic 
mechanisms relevant to the pathogenesis of AOS. Through this work, we identified novel 
heterozygous mutations of NOTCH1, providing independent verification of a critical role for 
this gene as a common cause of AOS in both autosomal dominant and sporadic cases. We 
have further used gene expression studies to examine the impact of NOTCH1 mutation on 
downstream signaling and demonstrated a pathogenic effect in RNA extracted from AOS 
subjects harboring NOTCH1 defects. These cases display a striking genotype-phenotype 
correlation with a high prevalence of cardiac and vascular anomalies, highlighting the 
importance of Notch signaling in cardiovascular development and demonstrating a novel 
role for NOTCH1 in multiple developmental processes that include scalp and limb 
formation.
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Methods
Patient cohorts
Exome sequencing was performed for 12 unrelated probands, diagnosed with autosomal 
dominant AOS and negative for ARHGAP31 and RBPJ mutations. Criteria for diagnosis 
were according to the guidelines by Snape et al.5 Subsequent mutation screening of the 
NOTCH1 coding regions comprised a cohort of 52 additional individuals with a diagnosis of 
AOS (n=11 autosomal dominant, n=41 isolated cases with no known family history). 
Cardiac clinical evaluation and echocardiography of NOTCH1-positive patients and family 
members was conducted at specialist cardiology centers (UK, Germany, Italy, France) 
following referral by the respective consultant clinical geneticist. The study complies with 
the Declaration of Helsinki and informed written consent was obtained from all participants 
before taking part. The research protocol was approved by the local ethics committees 
(NRES Committee London (Bromley), UK and the Ethics Board of the Medical Faculty of 
the University of Erlangen, Germany). Patient samples were collected as either saliva 
(Oragene DNA collection kit, DNA Genotek) or blood, and genomic DNA was extracted 
according to standard protocols.
Exome sequencing and mutation detection
Exome libraries were generated with the SureSelect Human All Exon Target Enrichment kit 
(Agilent Technologies) using genomic DNA extracted from peripheral blood. Paired-end 
sequence reads were generated on an Illumina HiSeq 2000. Read alignment to the reference 
genome (hg19) and variant calling were performed as described previously,6 with variant 
annotation completed using the ANNOVAR software.13 Sequence variants were compared 
against publicly available databases (HapMap, 1000 Genomes Project, dbSNP, the NHLBI 
Exome Sequencing Project (ESP) Exome Variant Server, and an in-house repository of 400 
exomes) to assess their novelty. Candidate genes were prioritized on the basis of novel 
truncating mutations (frameshift, nonsense, splice-site) in two or more independent 
probands. Of these, NOTCH1 was taken forward for further study due to compelling 
biological relevance to AOS pathogenesis. Validation of variant segregation and mutation 
screening of all NOTCH1 coding regions and intron-exon boundaries was performed by 
direct DNA sequencing using BigDye Terminator v3.1 chemistry on an ABI3730xl (Applied 
Biosystems).
Mutagenesis and cell culture
Wild-type NOTCH1 cDNA in pFN1A (Kazusa DNA Research Institute)14 was purchased 
from Promega. Identified AOS missense variants were introduced by site-directed 
mutagenesis using the QuikChange II XL kit (Agilent Technologies). Primer details are 
available on request. Cells were maintained at 37°C in a humidified incubator with 5% CO2. 
Human endometrioid cancer (HeLa) cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) with Glutamax (Gibco Life Technologies), supplemented with 10% fetal 
bovine serum. HeLa cells were seeded in 100 mm dishes and grown to 80% confluence. 
Transient transfection was performed using FuGene HD transfection reagent (Promega) and 
transfected cells were incubated for 48 hours before harvesting for RNA extraction.
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Gene-expression analysis
Total RNA was extracted from 2.5 ml of peripheral blood from NOTCH1-positive patients 
and a 26 year old clinically unaffected female control using the PAXgene Blood RNA 
System (PreAnalytiX), following the manufacturer’s guidelines. For mutagenized 
constructs, RNA was extracted from transfected cells with the RNeasy Mini kit (Qiagen), 
according to the manufacturer’s instructions. 500 ng of RNA was used for first strand cDNA 
synthesis with the High Capacity cDNA Reverse Transcription kit (Applied Biosystems). 
Quantitative real-time PCR was performed on a StepOnePlus real-time PCR machine 
(Applied Biosystems) using double-dye Taqman-style detection chemistry with the 
PrimerDesign 2× Precision Mastermix and custom-designed probe sets for NOTCH1, HEY1 
and HES1 mRNAs (PrimerDesign). GAPDH and ACTB house-keeping genes were used for 
normalization in mRNA relative quantifications using SDS v2.2 software. Gene of interest 
expression levels for patient and mutagenized samples were calculated by the 2−ΔΔCt method 
relative to the wild-type baseline. Statistical analysis of real-time data was performed using 
a Mann-Whitney test to generate two-tailed p values (VassarStats software).
Results
Clinical features of NOTCH1 positive families
The proband of family 1 (1-II:1) displayed cutis aplasia and marked TTLD at birth. The 
sibling 1-II:2 was also born with a severe cutaneous and bony scalp defect, with TTLD 
affecting both feet. On examination, the obligate carrier mother (1-I:3) exhibited no scalp or 
limb defects, but was found to have an unexplained heart murmur. Subject 1-I:1 had died at 
5 months due to a congenital heart defect, but no further details were available. Patient 1-II:4 
presented with syndactyly of the left hand and both feet, and CMTC on the abdomen and 
legs. Echocardiography revealed mild aortic stenosis and mild aortic regurgitation. Similar 
digit abnormalities and scalp ACC were displayed by subject 1-III:1. Although 1-III:2 
appeared clinically normal on examination, sonography of the heart also revealed mild aortic 
regurgitation (Table 1).
Family 2 has been previously described by Dallapiccola et al.15 The proband (2-II:1) and his 
mother both exhibited ACC of the midline region of the scalp and cardiac investigation by 
ultrasonography identified coarctation of the aorta in both individuals. The mother (2-I:2) 
also had a vascular anomaly consisting of duplication of the right femoral artery. Surgical 
intervention to repair the aortic coarctation and femoral artery duplication were conducted at 
14 and 17 years of age, respectively. The cardiac defect in subject 2-II:1 resembled the so-
called ‘Shone’s complex’, an anatomic variant consisting of multiple levels of left-sided 
obstructive CHDs,3,18 including aortic coarctation, bicuspid aortic valve, and parachute non-
stenotic mitral valve with mild regurgitation. Coarctectomy was performed at 5 months of 
age.
Patient 3-III:1 was born with a large area of scalp ACC with an underlying calvarial defect 
and shortened distal phalanges of the toes (Figure 1). A recent echocardiography detected no 
obvious abnormality. The obligate carrier father (3-II:2) was clinically normal and 
cardiology examination was negative for cardiac defects. The relative 3-II:3 was considered 
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to be affected with minor terminal hypoplasia of the phalanges of some toes but no cardiac 
anomaly was detected on sonography.
The proband of family 4 (4-II:1) presented with scalp ACC of the posterior parietal region 
and brachydactyly of both hands. Cardiovascular abnormalities included coarctation of the 
aorta, valvular aortic stenosis, parachute mitral valve with valvular insufficiency, and a 
subaortic membranous ventricular septal defect (VSD), also indicative of Shone’s complex. 
Aortic coarctation was operated at 15 days of life; aortic valvulotomy and intervention for 
VSD were performed at 9 years of age. Aortic valve substitution surgery was completed at 
23 years old. Echocardiography in the mother (4-I:2) revealed valvular aortic stenosis with 
thick fibrotic semilunar valves, moderate aortic valve insufficiency, and mild to moderate 
left ventricular hypertrophy (Table 1).
Specific clinical features of sporadic cases 5–11 are summarized in Table 1. Representative 
images of the limb and scalp defects observed across our AOS cohort are shown in Figure 1.
Identification of novel NOTCH1 variants
The analysis of exome profiles of affected male probands from families 1 and 2 identified 
novel heterozygous variants (c.1649dupA; p.Y550* and c.6049_6050delTC; p.S2017Tfs*9) 
in the NOTCH1 gene (NM_017617.3). Both mutations are predicted to result in premature 
stop codons of the mRNA transcript. Examination of available members of family 1 
confirmed segregation of the c.1649dupA mutation with the phenotype (Figure 2). 
Unfortunately, DNA was not available from the affected mother of proband 2-II:1 for 
segregation analysis of the c.6049_6050delTC variant.
Subsequent mutation screening of the NOTCH1 coding regions was performed in an 
extended replication cohort of 52 individuals with a clear clinical diagnosis of AOS. Novel 
NOTCH1 heterozygous variants were identified in 9 additional subjects. Taken together with 
the exome data, we report a total of ten distinct heterozygous mutations in the NOTCH1 
gene, one of which (c.1343G>A; p.R448Q) is recurrent, in 4 autosomal dominant families 
and 7 apparently sporadic cases with no known family history (Figure 2; Table I in the Data 
Supplement). All variants were confirmed by independent Sanger sequencing and absent 
from public variant databases. In families, segregation of the observed variant was 
consistent with the disease phenotype where DNA from multiple family members was 
available (Figure 2). In AOS mutation carriers with no family history of AOS or isolated 
cardiovascular disease, the sequencing of available parental DNA demonstrated that three 
mutations occurred de novo, namely c.1343G>A (p.R448Q) in proband 5-II:1, c.1345T>C 
(p.C449R) in proband 6-II:1 and c.1367G>A (p.C456Y) in proband 10-II:1. In Family 3, 
two unaffected paternal uncles and two clinically normal siblings of the proband 3-III:1 
were negative for the c.4120T>C (p.C1374R) mutation (data not shown). However, the 
unaffected obligate carrier father (3-II:2) was confirmed to carry the mutation. Similarly, the 
unaffected mother of subject 7-II:1 was found to harbor the c.1220C>G (p.P407R) variant. 
Cardiovascular assessment of 3-II:2 and 7-I:2 by echocardiography detected no underlying 
cardiac abnormality, confirming that these mutation carriers are phenotypically normal and 
demonstrating incomplete penetrance for mutations in this gene.
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NOTCH1 missense mutations are located within critical functional domains
Five of the six missense mutations identified in this study are predicted to be pathogenic by 
MutationTaster2,19 PolyPhen-2,20 and/or SIFT prediction software21 (Table II in the Data 
Supplement). The affected amino acids are located across the length of the receptor, in the 
main situated within the extracellular EGF-repeat domain. Specifically, four mutations 
(p.P407R, p.R448Q, p.C449R and p.C456Y) occur in or adjacent to the ligand-binding 
domain, specified by EGF repeats 11-13 (Figure 3A, Figure 4). The majority are strongly 
conserved across species and lie within highly conserved domains of the protein (Figure 
3B). Further, three amino acid substitutions (p.C449R, p.C456Y and p.C1374R) affect 
cysteine residues, which are likely to disrupt disulfide bonds that are critical for the structure 
of EGF-like domains (Figure 4). By contrast, the p.A1740S mutation is located within the 
transmembrane domain and, while conserved across mammalian species, is not conserved in 
other vertebrate species and has a less clear impact upon the structural integrity of the 
receptor so remains a variant of unknown significance (Figure 3).
NOTCH1 haploinsufficiency is implicated in AOS pathogenesis
To assess the level of mutant mRNA transcripts, we conducted quantitative real-time PCR 
studies using RNA extracted from peripheral blood of three patients harboring NOTCH1 
mutation (c.1343G>A and c.1649dupA (2 cases)). NOTCH1 transcript levels were 
significantly reduced by comparison to an unaffected control individual, demonstrating 
approximately 50% expression in all samples tested (Figure 5A). Whilst institutional ethical 
constraints precluded detailed cardiac evaluation of the control subject, it was made clear by 
personal testimony that there was no family history of developmental abnormalities relating 
to AOS-CHD. We additionally performed transient transfection of mutagenized NOTCH1 
constructs to examine the functional impact of missense mutations for which patient RNA 
was not available. Real-time PCR of RNA extracted from transfected cells also showed a 
significant decrease of NOTCH1 expression when compared to cells transfected with a full-
length wild-type construct and provided independent verification of NOTCH1 down-
regulation for the c.1343G>A mutation (Figure I in the Data Supplement).
To further interrogate the effect of NOTCH1 mutations on downstream signaling factors, we 
next performed gene expression studies to quantify the levels of HEY1 and HES1 transcript 
in patient-derived RNA samples. Subjects harboring the c.1649dupA frameshift mutation 
exhibited a particularly marked reduction of HEY1 transcript levels by comparison to wild-
type control (p=0.0004). By contrast, down-regulation of HEY1 expression was less 
profound for the c.1343G>A missense mutation (Figure 5B). In addition, HES1 mRNA 
levels were reduced in the c.1649dupA patients (p=0.0004); however, no significant 
deviation to the wild-type control was observed in the c.1343G>A sample (Figure 5C).
Discussion
Molecular genetic studies of AOS have successfully provided vital insights into the 
pathways relevant to the pathogenesis of this serious disorder of morphogenesis, through the 
identification of multiple causative genes. Yet, there remains substantial unexplained locus 
heterogeneity with the underlying molecular genetic determinants still uncharacterized for 
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the majority of cases. This degree of locus heterogeneity is uncommon for a rare disorder 
and suggests that AOS may represent a cluster of phenotypes with a related etiology, 
analogous to the RASopathies or ciliopathies.23,24
Herein, we report 10 novel germline NOTCH1 mutations in a patient cohort with autosomal 
dominant and sporadic forms of AOS. By comparison to AOS cases reported in the literature 
(13-20%),3-5,25,26 a significantly higher proportion of probands (5/11; 45%) presented with 
a congenital heart abnormality (Table 1). Similarly, cardiovascular anomalies were 
identified in 47% (8/17) of all affected variant carriers, thereby indicating that NOTCH1 
variants may represent a distinct subtype of AOS associated with cardiac malformations. A 
number of vascular complications, including CMTC and portal vein abnormalities, were 
additionally observed in NOTCH1-positive cases. Importantly, two of the probands in this 
study and two related mutation carriers have not undergone echocardiographic assessment; 
therefore we are unable to define the exact proportion of NOTCH1-positive cases with 
cardiovascular defects. In contrast to other gene reports, these patients predominantly 
demonstrate ACC with mild TTLD, affecting only terminal phalanges with nail hypoplasia 
(Figure 1). This study is further corroborated by a recent report of distinct NOTCH1 
mutations in 5 kindreds with AOS and cardiac spectrum defects.11
Emerging evidence is accumulating to implicate defects of the Notch signaling pathway in 
the pathogenesis of AOS. The Notch family of single-pass transmembrane receptors is well 
documented as playing a vital role in multiple cellular processes during embryogenesis and 
Notch pathway members have an established role in development of the cardiovascular 
system.27 Mutations in a subset of Notch components have been shown to underlie CHDs in 
both mice and humans but in exclusion of limb and scalp developmental abnormalities. For 
example, variants in the JAG1 gene, encoding a Notch ligand, underlie the majority of cases 
of Alagille syndrome28 whilst endothelial-specific deletion of Jag1 in the mouse leads to 
embryonic lethality and cardiovascular defects.29 NOTCH2 mutations account for a 
proportion of Alagille syndrome cases;30 however, distinct truncating variants in the 
terminal exon of NOTCH2 also lead to the osteolytic developmental disorder Hajdu-Cheney 
syndrome, indicating pleiotropic effects analogous to the NOTCH1 receptor.31,32 Of interest, 
mice homozygous for a targeted Jag2 deletion die perinatally due to craniofacial 
abnormalities and syndactyly of the fore- and hindlimbs, consistent features of the AOS 
spectrum.33 Furthermore, both Notch1 and Notch2 play key roles during mouse limb 
development in the regulation of apoptosis, a process mediated by Notch signaling through 
Jag2 in the apical ectodermal ridge,34,35 and the positive regulation of vascular growth 
through the promotion of angiogenesis and osteogenesis in bone.36 Despite numerous 
studies in lower organisms, the function of NOTCH1 during human fetal development 
remains to be fully elucidated.
In mammalian cells, canonical signaling through the Notch family (Notch1-4) is stimulated 
by ligand binding at the cell surface, which leads to proteolytic cleavage of the Notch 
intracellular domain (NICD), allowing for the formation of a transcriptional complex with 
RBPJ and co-activators (Figure 6).37 RBPJ is known to regulate the expression of the basic 
helix-loop-helix (bHLH) transcription factors HES1 and HEY1, both of which are related to 
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the Drosophila hairy and enhancer of split 1 gene. The stimulation of HES1 and HEY1 gene 
expression is therefore a direct readout of Notch signaling activation.
In this study, we report predicted protein truncating mutations (4/10) most likely to be 
subject to nonsense-mediated decay. The N-terminal ligand-binding domain of NOTCH1 
consists of a series of 36 EGF-like repeats. The majority (5/6) of the missense mutations 
identified in this study affect residues located within EGF domains of the receptor. These 
individual domains are characterized by a core β-pleated sheet, three disulfide bonds along 
with a series of variable loops.38 Within this region, EGF repeats 11-13 have been shown to 
be implicated with chelating Ca2+ which is essential for the maintenance of NOTCH1 
function.38,39 Three of the identified amino acid substitutions resulting in AOS (p.R448Q, 
p.C449R and p.C456Y) lie within EGF11 and potentially perturb function by disrupting the 
tertiary structure and affecting Ca2+ binding and/or ligand interaction. The X-ray structure 
of this region of wild-type NOTCH1 indicates that the side chains of Arg448 and Glu424 
interact electrostatically (Figure 4),22 thereby it is anticipated that the p.R448Q mutant is 
unstable. Similarly, the p.C449R and p.C456Y mutations will likely abolish the disulfide 
bonds between Cys440 and Cys449, and between Cys456 and Cys467, respectively, thereby 
disrupting the stability of the adjacent Ca2+ coordinated by the side chains Asp469, Glu455 
and Asp452 (Figure 4). Whilst the 3-dimensional structure of the EGF35 region has not been 
experimentally resolved, it is anticipated that a similar effect would be seen with the 
Cys1374 mutation. Taken together, these observations imply that the majority of missense 
mutations have a substantial effect on the structural integrity vital to NOTCH1 activity. 
Determining the functional impact of the transmembrane domain mutation p.A1740S is 
outside the scope of this study and is therefore of unknown significance.
The 36 EGF-like repeats can be modified by the addition of an O-glucose sugar between the 
first and second conserved cysteines, and an O-fucose between the second and third 
cysteines, which is essential for normal Notch function.40 Similarly, the target motif 
C5XXGXS/TGXXC6, located between the fifth and sixth conserved cysteines has been 
shown to be recognized by EOGT in both Drosophila and mouse.41 EOGT functions as an 
O-linked N-acetylglucosamine (GlcNAc) transferase, which catalyses the addition of an O-
GlcNAc moiety.42 Although EOGT has not yet been formally demonstrated to target human 
Notch, it is notable that 4 of the 5 EGF-domain specific missense mutations identified here 
are located within this target motif, suggestive of a convergence of pathways previously 
implicated in the development of AOS (Figure 3B).
To examine the effect of identified mutations on Notch signaling, we have performed gene 
expression studies and demonstrated that NOTCH1 expression is down-regulated in AOS 
subjects harboring NOTCH1 mutation in vivo, by comparison to a single healthy control 
female, aged 26 years. While it is not uncommon to use a single control in real-time PCR 
studies, we acknowledge that these findings might have been strengthened by employing 
additional controls as part of the experimental design. The data generated are corroborated 
by transient transfection studies of mutant constructs and, together, support the prediction of 
transcript loss by nonsense-mediated decay or, in the case of missense mutations, potential 
perturbation of mRNA stability.43 This observation is underpinned by a reduction of HEY1 
and, to a lesser extent, HES1 transcript levels. Of interest, perturbation of both HEY1 and 
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HES1 expression vary between the mutations tested, indicating allele-specific effects on 
downstream signaling. These data, whilst preliminary due in part to limited patient sample 
availability, suggest that down-regulation of HEY1 is a common mechanism in AOS. HEY1 
is known to have a prominent role in cardiovascular development, with Hey1/Hey2 double-
knockout mice exhibiting defects of vasculogenesis and remodeling, particularly in the head 
region.44 Moreover, these results are compatible with the hypothesis that dysregulated 
Notch signaling caused by identified mutations is mediated via the transcription factor 
RBPJ, a known causal factor in AOS pathogenesis. Taken together, these data offer support 
for loss-of-function or haploinsufficiency of NOTCH1 as an important factor in AOS 
pathogenesis, and provide a compelling genotype-phenotype correlation between NOTCH1 
mutation and AOS subjects with cardiac anomalies, which warrants further epidemiological 
investigation. As the overall study group herein has not been intensively examined for 
cardiac complications, these latter conclusions are at present indicative and will benefit from 
existing and future international collaboration.
This report establishes NOTCH1 mutation as the primary cause of AOS, accounting for 17% 
of cases in our cohort, and an important genetic factor in AOS with associated 
cardiovascular complications. Functional studies have indicated links to related genes 
associated with this condition, which together emphasize the central importance of the 
Notch signaling cascade in a series of key developmental systems in human embryogenesis.
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Figure 1. 
Clinical features of three representative AOS patients with NOTCH1 mutation. (left) Patient 
3-III:1 at age 2.8 years: residual skin defect after multiple operations on a large area of scalp 
aplasia cutis congenita; minor hypoplasia of terminal phalanges of the toes; normal fingers. 
(middle) Patient 6-II:1 as a newborn: large scalp defect involving the underlying bone; 
hypoplasia of terminal phalanges of both feet. (right) Patient 8-II:1 at age 14.7 years: small 
area of alopecia marking a healed scalp defect; hypoplasia of terminal phalanges and nails of 
the left foot; normal fingers.
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Figure 2. 
Pedigree structures and sequence chromatograms of identified NOTCH1 mutations. 
Asterisks denote the families included in the exome sequencing discovery cohort. Probands 
are marked by the black arrows and asymptomatic carriers are indicated with black dots. For 
de novo mutations, paternity was confirmed by microsatellite analysis (data not shown). 
Key: +, wild-type allele; −, mutant allele.
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Figure 3. 
Location and conservation of NOTCH1 mutations. (A) Schematic of the NOTCH1 protein 
highlighting the critical functional domains. The AOS mutations identified in this study are 
arrayed below the schematic. Truncating mutations are marked in green type and orange 
depicts missense mutations. (B) Conservation of the 6 missense mutations across species. 
Conserved residues are highlighted in orange. The 4th, 5th and 6th conserved cysteines 
within the EGF domains are boxed. Accession numbers: H. sapiens: NP_060087.3; M. 
mulatta: AFH32544.1; C. lupus familiaris: XP_005625490.1 (predicted); M. musculus: 
NP_032740.3; G. gallus: NP_001025466.1; X. tropicalis: NP_001090757.1; D. rerio: 
NP_571377.2; T. rubripes: XP_003975158.1 (predicted); D. melanogaster: NP_476859.2.
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Figure 4. 
Ball and stick representation of the 3-dimensional structure of human NOTCH1 EGF repeats 
11-13. The positions of the adjacent AOS mutations p.R448Q and p.C449R are highlighted 
by the solid red arrows. The p.C456Y mutation is similarly marked. The solid black arrows 
indicate the disulfide bonds which would be abolished by the p.C449R and p.C456Y 
mutations, respectively. The side chains of the key Ca2+ ion coordinating residues (Asp452, 
Glu455 and Asp469) and Glu424 are indicated. Water molecules have been removed for 
clarity. Figure produced from the crystal structure (PDB ID: 2VJ3)22 using the PyMOL 
Molecular Graphics System.
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Figure 5. 
Real-time PCR of NOTCH1-positive patient samples. Graphs show levels of gene 
expression for (A) NOTCH1, (B) HEY1 and (C) HES1. Relative quantification of mRNA 
transcripts are calculated relative to the WT baseline value (set at 1) and normalized to 
endogenous GAPDH and ACTB levels. Graphs represent the mean of three independent 
experiments with error bars indicating SEM. The brackets denote individuals with identical 
NOTCH1 mutations. Key: *p<0.001; †p<0.01
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Figure 6. 
Simplified schematic of the canonical Notch signaling pathway. (A) The EGF-repeat 
domain of Notch is known to be glycosylated by EOGT in mammalian cells. Activation of 
the Notch signaling cascade is initiated by the binding of one of five ligands through direct 
contact of adjacent cells. (B) Ligand activation leads to cleavage and release of NICD, 
which translocates to the nucleus to form an active transcriptional complex with RBPJ, 
mastermind (MAML) and transcriptional co-activators (CoA). (C) In the absence of Notch 
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activation, RBPJ complexes with co-repressor proteins (CoR) to repress transcription of 
downstream genes. Mutations in EOGT and RBPJ have previously been identified in AOS.
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rto
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pe
rte
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n 
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PA
P: 
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 m
mH
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P:
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m
m
H
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V
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 W
oo
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PW
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 m
m
H
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 [1
2 y
r]:
 m
PA
P:
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m
m
H
g 
w
ith
 S
ild
en
af
il 
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at
m
en
t
[3
.5 
yr
]: 
HS
M
 an
d p
or
tal
 
hy
pe
rte
ns
io
n 
w
ith
 G
I b
le
ed
in
g;
 
O
PV
. R
ef
: G
ira
rd
 e
t a
l. 
20
05
 
(P
ati
en
t 1
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an
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i-A
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t a
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e
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 y
r
m
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[6
.5 
yr
]: 
art
eri
og
rap
hy
: 
EP
V
O
, l
ar
ge
 h
ep
at
of
ug
al
 
co
ro
n
ar
y 
ve
in
, t
in
y 
he
pa
to
pe
ta
l c
av
er
no
m
a
[6
.5 
yr
]: 
no
rm
al;
 [1
4 y
r]:
 no
rm
al
[6
.5 
yr
]: 
HS
M
 an
d p
or
tal
 
hy
pe
rte
ns
io
n;
 O
PV
. R
ef
: G
ira
rd
 e
t 
a
l. 
20
05
 (P
ati
en
t 2
);1
6  
Fr
an
ch
i-
A
be
lla
 e
t a
l. 
20
14
.17
−
,
 
ab
se
nt
; +
, p
re
se
nt
 (f
or 
AC
C:
 +,
 sm
all
 de
fec
t (
<5
 cm
); 
++
, la
rge
 de
fec
t (
>5
 cm
) w
ith
 un
de
rly
ing
 os
seo
us
 sk
ull
 de
fec
t; f
or 
TT
LD
: +
, fe
et 
or 
ha
nd
s o
nly
; +
+, 
bo
th 
fee
t a
nd
 ha
nd
s a
ffe
cte
d);
 A
CC
, a
pla
sia
 cu
tis
 
co
n
ge
ni
ta
; A
R,
 a
or
tic
 re
gu
rg
ita
tio
n;
 A
S,
 a
or
tic
 v
al
ve
 st
en
os
is;
 A
SD
, a
tri
al
 se
pt
al
 d
ef
ec
t; 
BA
V
, b
ic
us
pi
d 
ao
rti
c 
va
lv
e;
 C
M
TC
, c
ut
is 
m
ar
m
or
at
a 
te
la
ng
ie
ct
at
ic
a 
co
ng
en
ita
; C
oA
, c
oa
rc
ta
tio
n 
of
 th
e 
ao
rta
; E
PV
O
, 
ex
tr
a-
he
pa
tic
 p
or
ta
l v
ei
n 
ob
str
uc
tio
n;
 E
H
PV
T,
 e
xt
ra
-h
ep
at
ic
 p
or
ta
l v
ei
n 
th
ro
m
bo
sis
; G
I, 
ga
str
oi
nt
es
tin
al
; H
SM
, h
ep
at
os
pl
en
om
eg
al
y;
 L
V
H
, l
ef
t v
en
tri
cu
la
r h
yp
er
tro
ph
y;
 M
BT
S,
 m
od
ifi
ed
 B
la
lo
ck
–T
au
ss
ig
 
sh
un
t; 
M
G
: m
ed
ia
n 
gr
ad
ie
nt
; m
PA
P,
 m
ea
n 
pu
lm
on
ar
y 
ar
te
ria
l p
re
ss
ur
e 
(m
ea
su
red
 by
 ri
gh
t h
ea
rt 
ca
the
ter
iza
tio
n);
 nd
, n
ot 
de
ter
mi
ne
d; 
OP
V,
 ob
lite
rat
ive
 po
rta
l v
en
op
ath
y; 
PA
, p
ulm
on
ary
 at
res
ia;
 PG
, p
ea
k 
gr
ad
ie
nt
; P
M
V
, p
ar
ac
hu
te
 m
itr
al
 v
al
ve
; P
V
, p
ea
k 
ve
lo
ci
ty
; P
V
R,
 p
ul
m
on
ar
y 
va
sc
ul
ar
 re
sis
ta
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e;
 P
W
P,
 p
ul
m
on
ar
y 
w
ed
ge
 p
re
ss
ur
e;
 R
ef
:, 
re
fe
re
nc
e 
of
 c
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e 
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po
rt;
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TL
D
, t
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m
in
al
 tr
an
sv
er
se
 li
m
b 
de
fe
ct
s; 
V
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, v
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l s
ep
ta
l d
ef
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t. 
Su
bje
ct 
ide
nti
fie
rs 
ref
er 
to 
the
 pe
dig
ree
 st
ruc
tur
es 
in 
Fig
ure
 1.
 Th
e p
rob
an
d f
or 
eac
h f
am
ily
 is
 m
ark
ed
 w
ith
 an
 as
ter
isk
.
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